JP2011500841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500841A5 JP2011500841A5 JP2010531264A JP2010531264A JP2011500841A5 JP 2011500841 A5 JP2011500841 A5 JP 2011500841A5 JP 2010531264 A JP2010531264 A JP 2010531264A JP 2010531264 A JP2010531264 A JP 2010531264A JP 2011500841 A5 JP2011500841 A5 JP 2011500841A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- crystalline camptothecin
- hydrate
- crystalline
- camptothecin hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 14
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 14
- 229940127093 camptothecin Drugs 0.000 claims 14
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000011580 nude mouse model Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 231100001274 therapeutic index Toxicity 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/923,727 US7572803B2 (en) | 2007-10-25 | 2007-10-25 | Hydrated crystalline esters of camptothecin |
| US11/923,727 | 2007-10-25 | ||
| PCT/US2008/081047 WO2009055633A1 (en) | 2007-10-25 | 2008-10-24 | Hydrated crystalline esters of camptothecin for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500841A JP2011500841A (ja) | 2011-01-06 |
| JP2011500841A5 true JP2011500841A5 (OSRAM) | 2011-10-13 |
| JP5487111B2 JP5487111B2 (ja) | 2014-05-07 |
Family
ID=40229972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531264A Expired - Fee Related JP5487111B2 (ja) | 2007-10-25 | 2008-10-24 | 癌の治療のためのカンプトテシンの水和結晶性エステル |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7572803B2 (OSRAM) |
| EP (1) | EP2205605B1 (OSRAM) |
| JP (1) | JP5487111B2 (OSRAM) |
| KR (1) | KR20100082358A (OSRAM) |
| CN (1) | CN101730701B (OSRAM) |
| BR (1) | BRPI0816584A2 (OSRAM) |
| CA (1) | CA2703054C (OSRAM) |
| ES (1) | ES2396222T3 (OSRAM) |
| MX (1) | MX2010004332A (OSRAM) |
| RU (1) | RU2483071C2 (OSRAM) |
| WO (1) | WO2009055633A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013071053A1 (en) | 2011-11-11 | 2013-05-16 | The Christus Stehlin Foundation For Cancer Research | Rodent therapeutic model humanized for liver and bone marrow |
| US9387257B2 (en) * | 2014-01-17 | 2016-07-12 | Academia Sinica | Lung cancer specific peptides for targeted drug delivery and molecular imaging |
| US9675609B2 (en) * | 2015-11-11 | 2017-06-13 | Cao Pharmaceuticals Inc. | Nano- and micro-sized particles of 20-camptothecin or derivative thereof and pharmaceutical compositions containing same, and treatment of cancers therewith |
| TW202128189A (zh) * | 2019-11-20 | 2021-08-01 | 美商威瓦西塔腫瘤公司 | 使用喜樹鹼衍生物之癌症治療 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552154A (en) | 1989-11-06 | 1996-09-03 | The Stehlin Foundation For Cancer Research | Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof |
| US6080751A (en) | 1992-01-14 | 2000-06-27 | The Stehlin Foundation For Cancer Research | Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof |
| US5352789A (en) | 1993-02-25 | 1994-10-04 | The Stehlin Foundation For Cancer Research | Methods for purifying camptothecin compounds |
| US5527913A (en) | 1993-02-25 | 1996-06-18 | The Stehlin Foundation For Cancer Research | Methods for purifying camptothecin compounds |
| US5731316A (en) | 1996-01-30 | 1998-03-24 | The Stehlin Foundation For Cancer Research | Derivatives of camptothecin and methods of treating cancer using these derivatives |
| US6096336A (en) | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| US6407118B1 (en) | 1996-01-30 | 2002-06-18 | The Stehlin Foundation For Cancer Research | Derivatives of camptothecin and methods of treating cancer using these derivatives |
| USRE38408E1 (en) | 1997-08-05 | 2004-01-27 | The Stehlin Foundation For Cancer Research | Methods of preparing and purifying 9-nitro-20-camptothecin |
| US5922877A (en) | 1997-08-05 | 1999-07-13 | The Stehlin Foundation For Cancer Research | Methods of preparing and purifying 9-nitro-20-camptothecin |
| US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| US6228855B1 (en) | 1999-08-03 | 2001-05-08 | The Stehlin Foundation For Cancer Research | Aromatic esters of camptothecins and methods to treat cancers |
| US6703399B2 (en) | 2002-05-06 | 2004-03-09 | The Stehlin Foundation For Cancer Research | Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds |
| US6699875B2 (en) | 2002-05-06 | 2004-03-02 | The Stehlin Foundation For Cancer Research | Cascade esters of camptothecins and methods of treating cancer using these compounds |
| KR101095382B1 (ko) * | 2003-02-25 | 2011-12-16 | 가부시키가이샤 야쿠르트 혼샤 | 이리노테칸 염산염의 결정다형의 제조방법 |
| TWI333492B (en) * | 2003-11-12 | 2010-11-21 | Smithkline Beecham Cork Ltd | Crystalline topotecan hydrochloride product and preparation thereof |
| EP2082741A1 (en) * | 2005-09-20 | 2009-07-29 | Scinopharm Singapore Pte, Ltd. | Novel crystal form of irinotecan hydrochloride |
-
2007
- 2007-10-25 US US11/923,727 patent/US7572803B2/en active Active
-
2008
- 2008-10-24 KR KR1020107011223A patent/KR20100082358A/ko not_active Ceased
- 2008-10-24 WO PCT/US2008/081047 patent/WO2009055633A1/en not_active Ceased
- 2008-10-24 JP JP2010531264A patent/JP5487111B2/ja not_active Expired - Fee Related
- 2008-10-24 MX MX2010004332A patent/MX2010004332A/es active IP Right Grant
- 2008-10-24 BR BRPI0816584-0A2A patent/BRPI0816584A2/pt not_active IP Right Cessation
- 2008-10-24 CN CN200880013536XA patent/CN101730701B/zh not_active Expired - Fee Related
- 2008-10-24 RU RU2010120810/04A patent/RU2483071C2/ru not_active IP Right Cessation
- 2008-10-24 EP EP08841603A patent/EP2205605B1/en not_active Not-in-force
- 2008-10-24 ES ES08841603T patent/ES2396222T3/es active Active
- 2008-10-24 CA CA2703054A patent/CA2703054C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510123A5 (OSRAM) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2013535491A5 (OSRAM) | ||
| JP2008535902A5 (OSRAM) | ||
| JP2009536191A5 (OSRAM) | ||
| JP2009242409A5 (OSRAM) | ||
| JP2012516900A5 (OSRAM) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2016536352A5 (OSRAM) | ||
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| JP2013510120A5 (OSRAM) | ||
| JP2009514870A5 (OSRAM) | ||
| JP2013510124A5 (OSRAM) | ||
| JP2015519347A5 (OSRAM) | ||
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| JP2014507391A5 (OSRAM) | ||
| JP2017526662A5 (OSRAM) | ||
| JP2014530181A5 (OSRAM) | ||
| RU2016116789A (ru) | Комбинация энзалутамида и афурезертиба для лечения рака | |
| JP2011500841A5 (OSRAM) | ||
| JP2017503753A5 (OSRAM) | ||
| JP2009502777A5 (OSRAM) | ||
| JP2013528215A5 (OSRAM) | ||
| CN101773499A (zh) | 延胡索乙素的新用途 | |
| JP2012528186A5 (OSRAM) |